Gaseous nitrogen oxide (gNO) is an important indoor and outdoor air pollutant. Many studies have indicated gNO causes lung tissue damage by its oxidation properties and free radicals. However, there are considerably few data on the association between lung cancer and gNO exposure. The purpose of this study was to examine whether gNO could contribute to the process of malignant progression of lung cancer. The results of woundhealing assay and in vitro transwell assay revealed that gNOinduced dose and time dependently the migration and invasion of A549 cells, a human lung cancer cell line, under noncytotoxic concentrations. gNO was able to induce release of NO from A549 cells, an effect that was mediated via the activation of inducible nitric oxide synthases (iNOS), but not constitutive isoforms, during the same treatment period. An increased expression of matrix metalloproteinase (MMP) and a coincided reduction in repress tissue inhibitors of metalloprotease-2 were observed upon the treatment of gNO. The gNO-mediated MMP-2 induction appeared to be a consequence of nuclear factor kappa B and activation protein-1 activation, because that their DNA binding activity was enhanced by gNO. All these influences of gNO were efficiently repressed by the pretreatment of a NOS inhibitor (N G -nitro-Larginine methyl ester). Using a mouse model, we showed that gNO promoted A549 metastasis to the lung through a mechanism involving the iNOS-dependent MMP-2 activity. Our data imply that gNO exposure, which in turn led to iNOS activation and the enhancement of MMP-mediated cellular events, was related to lung cancer development.
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Gaseous nitrogen oxide (gNO), a air pollutant existed in the atmosphere, could be generated from several sources including motor vehicles, outdoor facilities for heating and power generation, and some indoor appliances, all of which burn fossil fuels (Leaderer, 1982) . The other primary source for personal exposure to gNO is cigarette smoke, which contains up to 600 lg of nitric oxide (NO) per cigarette in the gas phase (Yoshie and Ohshima, 1997) . Endogenous NO is produced from L-arginine via nitric oxide synthases (NOS), of which three distinct isoforms have been identified. The two constitutive isoforms, endothelial NOS (eNOS) and neuronal NOS (nNOS), are calcium/calmodulin dependent, whilst the activity of the calcium/calmodulin-insensitive inducible isoform (iNOS) is predominantly regulated at the transcriptional level in response to cytokines and bacterial lipopolysaccharide (Moochhala and Rajnakova, 1999) . NO involves in numerous physiological as well as pathological mechanisms such as vasodilatation, inflammation and malignant transformation (Gauthier et al., 2004; Jadeski et al., 2000) . Demonstration of NO and iNOS expression in various solid tumors and their metastases, and as well as in tumor cell lines has suggested that this biological mediator may participate in tumor survival and metastatic process (Gauthier et al., 2004) . Total NOS activity is also increased in carcinomas of the larynx and oral cavity (Gallo et al., 1998) , and in adenocarcinomas of the lung (Fujimoto et al., 1997) relative to normal healthy control tissue.
Lung cancer is the leading cause of death among cancers worldwide. This high mortality is attributed to its early metastasis, especially for non-small-cell lung carcinoma (NSCLC) (Greenlee et al., 2001) . Tumor metastasis occurs by a series of steps including vessel formation, cell attachment, invasion, and cell proliferation, and is regulated by extremely complicated mechanisms (Fidler, 2005) . Identification of key proteins involved in the processes, such as urokinase-type plasminogen activator (uPA) and matrix metalloproteinases (MMPs), is vital for understanding carcinogenesis and devising new therapies. The degradation of basement membranes and stromal extracellular matrix (ECM) are crucial steps for tumor invasion and metastasis. MMPs family of human zinc-dependent endopeptidases is responsible for degradation of the ECM (Parks and Shapiro, 2001) . Among them, the gelatinases (MMP-2 and MMP-9) efficiently degrade native collagen types IV and V, fibronectin, entactin, and elastin. In addition, uPA may initiate the activation of an enzymatic cascade that involves the activation of plasminogen to plasmin and of pro-MMPs to MMPs (Duffy and Duggan, 2004) . Furthermore, the expression of MMPs or uPA are primarily regulated at the transcriptional level through activation protein-1 (AP-1) or nuclear factorkappaB, and at the protein level via their activators or inhibitors, and their cell surface localization (Aguirre Ghiso et al., 1999; Westermarck and Kahari, 1999) .
The roles of NO in lung carcinogenesis, including initiation, promotion and malignant progression, have been extensively studied. Overall, an overwhelming amount of evidence suggests a positive association between gNO and lung tumorgenesis (Jadeski et al., 2000) . Our previous studies using human lung fibroblast cells demonstrated that the treatment of gNO resulted in the formation of DNA adduct 8-nitroguanine, an increased synthesis of iNOS, and an elevated production of intracellular nitrite. These data suggested the involvement of gNO in the nitration of DNA that might be important for the carcinogenicity of gNO (Hsieh et al., 2001) . We also provided evidences to suggest gNO as a tumor promoter characterized by its ability to stimulate cell proliferation and inflammation, as well as the ability to repress benzo[a]pyrene-induced MRC-5 apoptosis (Chen et al., 2003 (Chen et al., , 2005 . However, further studies on the definitive mechanisms of the metastatic activities of gNO in vitro and in vivo are needed; thus, the objective of the present study was to determine whether gNO could modify the process of malignant progression of lung cancer. Moreover, although many previous reports have investigated the role of iNOS in promoting cell proliferation (Asano et al., 1994; Chou et al., 2002) , the role of gNO in inducing iNOS to promote lung tumor progression remains paradoxical.
In order to define in more detail the role of gNO in the metastatic process, tumor cell lines were treated with gNO and examined for the followings: (1) the relationship between the expression of NOS and the migration, invasion and metastasis ability of tumor cells, (2) the involvement of NOS-dependent MMPs production to the migratory or invasive abilities in vitro and to the biological behavior in vivo (i.e., tumor mass and capacities for lung nodule formation), and (3) the molecular mechanisms of gNO-mediated malignant progression of human lung carcinoma.
MATERIALS AND METHODS
Chemicals. gNO (10,000 ppm in N 2 ) and N 2 were obtained from Sanfa Co. (Hsingcha, Taiwan). Tris-HCl, ethylenediaminetetraacetic acid (EDTA), sodium dodecyl sulfate (SDS), phenylmethylsulfonyl fluoride, bovine serum albumin, leupeptin, Nonidet P-40, deoxycholic acid, sodium orthovanadate aprotinin, dimethyl sulfoxide, RNase A, proteinase K, DNase, and polyclonal antibody against b-actin were purchased from Sigma Chemical Co. (St Louis, MO). Protein assay kit was obtained from Bio-Rad Labs. (Hercules, CA). Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), penicillin-streptomycin mixed antibiotics, L-glutamine, Dulbecco's phosphate buffer solution (PBS), and trypsin-EDTA, were purchased from Gibco/BRL (Gaithersburg, MD). Polyclonal antibodies against eNOS, nNOS, iNOS, MMP-2, TIMP-2, NF-jB, c-Jun, c-Fos and C23 were from Santa Cruz Biotech. (Santa Cruz, CA). The enchanced chemiluminescence (ECL) kit was purchased from Amersham Life Science (Amersham, UK).
Cell culture and treatment. Three kinds of human lung cancer cell lines, H1355 (derived from lung epidermoid carcinoma), H1299 (derived from lung carcinoma), and A549 (derived from alveolar epithelial carcinoma), were obtained from ATCC (Manassas, VA). The cells were cultured in growth media prepared according to ATCC recommendations and supplemented with 10% FBS, 2mM glutamine and 100 U/ml penicillin-streptomycin mixed antibiotics. All cell cultures were maintained at 37°C in a humidified atmosphere of 5% CO 2 .
gNO-saturated buffer was prepared by bubbling through PBS with N 2 gas for 30 min to deoxygenate the solution, and then bubbling with authentic gNO (10,000 ppm) for another 30 min. The above-surface space was briefly spurted with N 2 . This saturated solution with an NO concentration of approximately 1.25mM, as measured by ISO-NO analyzer, was used for cell treatment. A549 cells seeded on 60-mm plastic dishes (5 3 10 6 cells per dish) were treated with gNO-saturated PBS (Chen et al., 2003) at various dilutions for the indicated time points (0-24 h) (as a gas-liquid interface culture system). After exposure, the cells were harvested, and cell extracts were prepared for immunoblot analysis. For the inhibition test, N G -nitro-L-arginine methyl ester (L-NAME) at 0.5mM was added 30 min before gNO treatment.
Measurement of NO concentration. NO production was assayed by measuring the concentration of nitrite (a stable degradation product of NO) in the cultured medium using the Griess reagent (Chang et al., 2002) . Briefly, A549 cells were cultured in 24-well culture plates. After reaching confluence, the culture medium was changed to phenol red-free DMEM. The cells were treated with gNO (5.0lM) or without for 0-24 h, and incubated in a humidified incubator at 37°C. After treatment, the cultured medium was removed, centrifuged, mixed with an equal volume of Griess reagent (1% sulfanilamide, 0.1% naphthylene diamine dihydrochloride, 2% phosphoric acid), and then incubated at room temperature for 10 min. The absorbance was measured at 550 nm in a microplate reader. Sodium nitrite (NaNO 2 ) was used for the standard curve of nitrite concentrations.
Assessment of cell viability. Cells were seeded at a density of 10 5 cells/ml and incubated with gNO at various concentrations (0, 1.0, 2.5, 5.0, 7.5, and 10.0lM) for 24 h. Thereafter, the medium was changed and 3-(4,5-dimethylthiazol-zyl)-2,5-diphenyltetrazolium bromide (MTT, 0.1 mg/ml) was added for 4 h. The viable cell number was directly proportional to the production of formazan which, following solubilization with isopropanol, was measured spectrophotometrically at 563 nm. The MTT assay was used to evaluate the effect of the test drugs on cell viability, as described previously (Alley et al., 1988) , and to determine the noncytotoxic concentrations.
Wound-healing assay. Culture cells were grown to confluent monolayer in six-well petri dishes for 24 h in serum-free medium (three dishes per group). The medium was replaced with serum-containing medium following the treatment of gNO at various concentrations (0, 1.0, 2.5, and 5.0lM); and the monolayers were disrupted (i.e., wounded) by scraping them with a P200 micropipette tip. At the indicated times (0, 6, 12, and 24 h) after scraping, the cells were washed twice in PBS (pH 7.4), and the number of cells in the denuded (scraped) zone of each dish was counted at 3100 magnification in a blinded fashion. Each dish was counted three times (Zhang et al., 2004) .
Cell invasion assay. A549 cells were incubated with gNO at various concentrations (0, 1.0, 2.5, and 5.0lM) for 24 h. Afterwards, the cells were removed by trypsinization and tested for in vitro invasiveness by the Boyden http://toxsci.oxfordjournals.org/ chamber invasion assay (Attiga et al., 2000) . Matrigel (Collaborative Biomedical Products, Bedford, MA) was diluted to 25 mg/50 ml with cold filtered distilled water, and applied to the 8-lm pore size polycarbonate membrane filters of Boyden chamber. The above treated cells were seeded to the upper part of Boyden chamber (Neuro Probe, Cabin John, MD) at a density of 3 3 10 5 cells/ml in 50 ll of serum-free medium. The bottom chamber contained standard medium with 10% FBS. After the chamber was incubated at 37°C for 6 h, the cells that had invaded to the lower surface of the membrane were fixed with methanol and stained with Giemsa. Cell numbers in randomly selected fields were counted under a light microscope at 3400 magnification.
Determination of MMP-2 and MMP-9 by zymography. The activities of MMP-2 and MMP-9 in the conditioned medium were measured by gelatinzymogram protease assays as described previously (Chu et al., 2004) . In general, samples were prepared with standard SDS-gel loading buffer containing 0.01% SDS without b-mercaptoethanol and boil before loading. The prepared samples (20 lg total protein) were then subjected to electrophoresis with 8% SDS polyacrylamide gels (0.75 mm thick, acrylamide/bis-acrylamide ¼ 30/1.2) containing 0.1% gelatin. After electrophoresis, gels were washed twice with 100 ml distilled water containing 2% Triton X-100 on a gyratory shaker for 30 min at room temperature to remove SDS and then incubated in 100 ml of reaction buffer (40mM Tris-HCl, pH 8.0, 10mM CaCl 2 , 0.02% NaN 3 ) for 12 h at 37°C. The gels were stained with Coomassie brilliant blue R-250 followed by and destaining with methanol-acetic acidwater (50/75/875, vol/vol/vol).
Western blot analysis. Western blotting was performed according to a method described previously (Chen et al., 2003) . The preparation of cytosolic and nuclear fractions of the cells was performed as described as previously (Ito et al., 2004) . The cell lysates were denatured in sample buffer containing SDS, and equal amounts of protein were separated on 8-15% SDS-polyacrylamide gels and transferred to nitrocellulose membranes (Millipore, Bedford, MA). After blocking with 5% nonfat dry milk, the membranes were incubated overnight at 4°C with the primary antibodies as indicated. In the subsequent day, the membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies, and detected with ECL reagent. The cytosolic and nuclear proteins were determined respectively by Western blotting using anti-b-actin and anti-C23 antibodies as loading controls. Protein levels were quantitated by densitometry using Alphalmager Series 2200 software (Alpha Innotech Corporation, San Leandro, CA).
Real-time quantitative reverse transcription-PCR. Total RNA was isolated from cells with a guanidinium chloride procedure as described previously (Chu et al., 2004) . The mRNA levels were analyzed by real-time quantitative reverse transcription-PCR (RT-PCR) using a Bio-Rad iCycler system (Bio-Rad, Hercules, CA) (Li et al., 2004) . The mRNAs were reversetranscribed into cDNAs by using an iScript cDNA synthesis kit (Bio-Rad). The specificity of primers was tested by running a regular PCR for 40 cycles at 95°C for 20 s and 60°C for 1 min followed by electrophoresis on an agarose gel. The real-time PCR was performed using a SYBR supermix kit (Bio-Rad) and run for 40 cycles at 95°C for 20 s and 60°C for 1 min. Each 20 ll of PCR mixture contained cDNA template, SYBR supermix kit, and 0.5lM of each gene-specific primer. Specific primers were designed using Beacon Designer 2.0 software (Premier Biosoft International, Palo Alto, CA). The lengths of all amplified products are between 75 and 150 bp. The sequences of each gene-specific primer are as follows: 5#-TGCAGACACGTGCGTTACTCC-3# (iNOS forward) and 5#-GGTAGCCAGCATAGCGGATG-3# (iNOS reverse); 5#-TCTCCTGACATTGAC-CTTGGC-3# (MMP-2 forward) and 5#-CAAGG-TGCTGGCTGAGTAGATC-3# (MMP-2 reverse); and 5#-CTGGACGTTGG-AGGAAAAGAAG-3# (TIMP-2 forward) and 5#-TGCTTATGGGTCCTC-GATGTC-3# (TIMP-2 reverse). The sequences for the house keeping gene, b-actin, are as follows: 5#-CTGGAACGGTGAAGGTGACA-3# (b-actin forward) and 5#-AAGGGACTTCCTGTAACAATGCA-3# (b-actin reverse). The PCR efficiency was examined by serial dilution of the cDNA, and the PCR specificity was checked by melting curve data. Each cDNA sample was triplicated and the corresponding no-RT mRNA sample was included as a negative control. The b-actin primers were included in every plate to avoid sample variations. The mRNA level of each sample for each gene was normalized to that of the b-actin mRNA.
Electrophoretic mobility shift assay (EMSA). The DNA binding activities of AP-1 and NF-jB in nuclear extracts were assessed by electrophoretic mobility shift assay (EMSA) (Ho and Ames, 2002) using the Lightshift kit from Pierce (Rockford, IL) with biotin-labeled double-stranded AP-1 or NF-jB oligonucleotides (Promega, Madison, WI). The binding reactions containing 10 lg of nuclear protein, 10mM Tris, 50mM KCl, 1mM dithiotreitol, 5mM MgCl 2 , 2 lg poly (dIÁdC), and 2 pmol of oligonucleotide probe were incubated at room temperature for 20 min. Specific binding was confirmed by a 200-fold excess of unlabeled probe as specific competitor. Protein DNA complexes were separated on a 6% nondenaturing acrylamide gel, and then transferred to positively charged nylon membranes and cross-linked in a Stratagene crosslinker (Stratagene, La Jolla, CA). Band shifts were visualized with a streptavidin-horseradish peroxidase followed by chemiluminescent detection.
Experimental metastasis. A549 cells were incubated with gNO at various concentrations (0, 2.5, and 5.0lM) in the absence or presence of L-NAME for 24 h. The cells were washed and resuspended in PBS. Subsequently, a singlecell suspension containing 10 6 cells in 0.1 ml of PBS was injected into the lateral tail vein of 6-week-old SCID mice (supplied by Laboratory Animal Center, Hualien, Taiwan). Mice were killed after 8 weeks. (Our preliminary study in this animal model indicated that A549 cells developed numerous lung metastasis nodules by 8 weeks). All organs were examined for metastasis formation (Chang et al., 2004) .
Histological evaluation. Immediately after sacrifice, the lungs were removed, weighed, and fixed in 10% formalin followed by paraffin embedding. The embedded tissue was then sectioned into 4-lm sections for pathologic evaluation by hematoxylin-eosin stain. The size and number of lung tumor nodules for each tissue section were measured and counted automatically by the software of the image analysis program Image-Pro Plus 4.5 (Media Cybernetics, MD) according to the different grayscale intensity of normal and pathological areas under a microscope. Lung nodules larger than 0.5 mm in diameter were counted. The lung tumor growth was quantified by measuring the tumors in two dimensions with calipers. Tumor volumes were calculated by the formula (a 3 b 2 ) p/6, where a and b are the longest and shortest diameters, respectively (Jenkins et al., 1995) . In addition, zymography assay was carried out with lung tissue extracts from the mice.
Statistical analysis. Data are reported with means ± standard deviation of three independent experiments and evaluated by one-way ANOVA. Significant differences were established at p < 0.05.
RESULTS

Noncytotoxicity of gNO to A549 Cells
gNO is reported to be carcinogenic as evidenced by its ability of stimulating MRC-5 cell proliferation and inflammation. In this study, we first determined the cytotoxicity of gNO by treating A549 cells (10 5 cells/ml) with gNO at various concentrations (0, 1.0, 2.5, 5.0, 7.5, and 10.0lM) for 24 h followed by MTT assay. Comparing to that of control (untreated with gNO), the viability of A549 cells was not significantly affected by gNO, even at a concentration as high as 5.0lM (Fig. 1A) . Therefore, it demonstrated that a 24 h treatment of gNO at a concentration ranging from 0 to 5.0lM has no cytotoxicity to A549 cells-a highly metastatic cancer cell line. This concentration range was then applied in all subsequent experiments. In addition, the same treatment was performed 366 CHEN ET AL.
on other lung cancer cell lines, H1355 and H1299, and similar results were obtained (data not shown).
NO Concentration in A549 Cells Culture Medium
To determine endogenous NO production by A549 cells, nitrite and nitrate were measured in the cultured medium using the Griess reaction. In the absence of any stimulation, the base level of endogenous NO produced by A549 cells was increased over a 24-h incubation. The treatment of gNO (5.0lM) enhanced significantly the release of NO from A549 cells over the same incubation period (Fig. 1B) .
Effects of gNO on the Motility and Invasion of A549 Cells
The effect of gNO on A549 cell migration was determined by wound-healing assay in which cells was induced to migrate by physical wounding of cells plated on fibronectin precoated plates. As shown in Figure 2A , when cells were treated with gNO for 6, 12, and 24 h, an apparent and gradual increase of cells in the denude zone was observed under a light microscopy. A549 cells exposed to 2.5 and 5.0lM of gNO were able to migrate and fill nearly the wounded area as compared with untreated cells. The quantitative data in Figure  2B revealed that gNO could stimulate A549 cells migration in a dose-and time-dependent manner.
To further examine the effect of gNO on the invasive ability of A549 cells, Boyden chamber coated with Matrigel was used in a dosage experiment. A549 cells treated with gNO (0, 1.0, 2.5, and 5.0lM) for 24 h were plated in the upper chamber and the number of cells moved to the underside of the coated membrane was counted 6 h later under a light microscopy. The results showed that the number of cells invaded to the lower chamber was significantly increased by the 24-h treatment of gNO. Such induction was concentrationdependent with a 3-fold increase (p < 0.01) when gNO was at 5.0lM (Figs. 2C and 2D ).
iNOS is Essential for the Inductive Effect of gNO on Cell Migration and Invasion
In order to determine which isoform of NOS was induced by gNO in A549 cells, Western blotting was applied to examine the protein levels of eNOS, nNOS and iNOS. The levels of the two constitutively expressed NOS isoforms, eNOS and nNOS, were not affected by the treatment of gNO (5.0lM). On the contrary, there was an induction in the protein level of iNOS in the gNO-treated cells, beginning 6-9 h after treatment (Fig.  3A) . Similar results were obtained for the mRNA levels of iNOS in the cells (Fig. 3B) .
Subsequently, to examine the involvement of iNOS in the gNO-induced cell migration and invasion, A549 cells were pretreated with a NOS inhibitor (L-NAME) that efficiently downregulated the protein and mRNA levels of iNOS under gNO exposure (p < 0.01) for 24 h (Figs. 3A and 3B ). A549 cells pretreated with L-NAME following a 24-h exposure to gNO (5.0lM) also displayed significant reductions in the cell numbers in the denude zone (68.4%) and in the lower chamber (63.5%), as compared with those of the gNO alone (cell numbers from 386 to 122 and from 96 to 35, respectively, p < 0.01) (Figs. 3C and 3D ). These results implied that inductive effect of gNO on A549 cell migration and invasion was acting through, in part, the activation of iNOS signaling.
iNOS-Dependent Activation of MMPs Activity in gNO-Treated A549 Cells
Because ECM degradation is crucial to cellular invasion, indicating the inevitable involvement of matrix-degrading proteinases (Duffy and Duggan, 2004; Parks and Shapiro, 2001) , the effects of gNO on MMPs and uPA activities were investigated by gelatin-and casein-zymography under a The nitrite and nitrate concentrations were measured at 550 nm by Griess reagent method after stimulation with gNO (5.0lM) or without for indicated times (0-24 h). The results were represented the average of three independent experiments ± SD. *p < 0.05, **p < 0.01 compared with the control.
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condition of serum starvation to clarify if MMPs or uPA were involved in the enhancement of invasion by gNO. The time course experiments of gNO (5.0lM) in the absence or presence of L-NAME (Fig. 4A, upper panel) revealed that an increase in the MMP-2 activity was detected 9 h after gNO exposure alone and continued to rise to 3.98-fold at 24 h (p < 0.01), whereas MMP-9 and uPA activities were not affected (data not shown). Furthermore, blocking the expression of iNOS by L-NAME diminished significantly the gNO-induced upregulation of MMP-2 activity (about 80.9%) in A49 cells (Fig. 4A, lower  panel) . This result indicated that the increase of MMP-2 production was mostly caused by the gNO-induced expression of iNOS.
Recent findings have demonstrated that endogenous NO promoted matrix degradation by mammary adenocarcinoma C3L5 cells via altering the balance between MMPs and their natural inhibitors, tissue inhibitors of metalloproteases (TIMPs) (Orucevic et al., 1999) . In order to further relate the regulatory effects of gNO on MMP-2 to its inhibitor, TIMP-2, Western blot analysis was performed. Although the protein level of MMP-2 was significantly elevated, that of TIMP-2 was reduced via gNO incubation (Figs. 4B and 4C) . The gNOinduced changes in the protein levels of MMP-2 and TIMP-2 coincided well with their mRNA levels as evidenced by realtime quantitative RT-PCR results (Figs. 4D and 4E ), indicating that gNO might regulate MMP-2 and TIMP-2 expressions at the transcriptional level. Here, we had also found that the pretreatment of L-NAME to A549 cells diminished the gNOregulated protein and mRNA levels of MMP-2 and TIMP-2 (Figs. 4B-E) . represented denotes the mean number of the cells expressed as a proportion of that untreated group and the average of three independent experiments ± SD. *p < 0.05, **p < 0.01 compared with the control. #p < 0.05, ##p < 0.01 compared with the respective time point of untreated group.
FIG. 3.
Effects of gNO on NOS expression. A549 cells were treated with 5.0lM gNO in the absence or presence L-NAME (0.5mM) for indicated times (0-24 h), and protein (A) and mRNA (B) levels of NOS were determined by Western blotting and real-time quantitative RT-PCR, receptively. b-Actin was served as an internal control. The quantitative data were presented as means ± SD of three repeats from one independent study. *p < 0.05, **p < 0.01 compared with 0-h control. #p < 0.05, ##p < 0.01 compared with the respective time point of gNO-treated group. Effects of a NOS inhibitor on gNO-induced A549 cell migration (C) and invasion (D). Cell migration and invasion were analyzed by wound-healing assay and Boyden chamber invasion assay. Results from three repeated and separated experiments were similar. 
Effects of gNO on NF-jB and c-Jun Nuclear Translocation
Levels Previous reports have demonstrated the MMP-2 promoter has several transcription-factor-binding motifs, including NF-jB and AP-1 (Westermarck and Kahari, 1999) . Therefore, the NF-jB and AP-1 signal transduction pathway may play an important role in the regulation of MMP-2 expression. We next tested whether gNO perturbed the translocation of NF-jB and AP-1 into the nucleus in A549 cells. The nucleus extracts were prepared and subjected to immunoblot analysis. Our data in Figures 5A and 5B, respectively, demonstrated that the nuclear levels of NF-jB (p65) and c-Jun were increased 6 h after the treatment of gNO in comparison with control. However, there was no noticeable change in c-Fos nuclear translocation within the same periods (data not shown). Figure 5 also illustrated the repressing effects of L-NAME on the gNO-induced translocation of NF-jB and c-Jun. These results suggested that iNOS activation responding to gNO treatment might lead to the translocation of NF-jB and c-Jun that, subsequently, executed MMP-2 production and cellular invasion in A549 cells. The DNA binding activities of the translocated NF-jB and AP-1 were further confirmed by EMSA analysis. As shown in Figure 6 , gNO enhanced the transcriptional activity of NF-jB (upper panel) and AP-1 (lower panel) 6 h after treatment and persisting through the next 12-24 h, a time span that coincided with the kinetics of cell migration and invasion.
Effects of gNO on A549 Metastasis to the Lung in a Mouse
Model The works described above clearly showed that in cultured cells gNO is a potent factor that promoted the migration, invasion and metastasis of cancer cells in cultured system. To give further support to this observation in an in vivo system, we used a well-established animal model to analyze the metastatic potential of gNO (Chang et al., 2004 ). In the model, the highly metastatic A549 cells were treated with gNO (2.5 and 5.0lM), and then injected into the lateral tail vein of SCID mice. Animals were examined for metastasis 8 weeks later, and the disseminated tumors formed principally in the lung.
The results of lung metastatic colonization was summarized in Table 1 . Notably, the treatment of gNO strongly enhanced the metastatic ability of A549 cells forming 1.38 and 4.83 metastatic nodules for group 3 and 4, respectively, whereas untreated cells forming only 0.33 ± 0.51 nodules. The cotreatment of L-NAME (group 5) inhibited significantly the formation of the gNO-induced metastatic nodules. Tumor volumes of the lung metastasis and the weights of lung were significantly increased in the gNO-pretreated A549 group (groups 3 and 4) as compared with that of untreated group (group 2). In the presence of gNO, group pretreated with L-NAME (group 5) showed decrease in the size and volumes of the lung nodules as well as the lung weights.
The levels of MMPs in the lung tissue with metastatic A549 cells treated with gNO were higher than those of tissue with control cells (Fig. 7) . This inductive effect of gNO was also repressed by the cotreatment of L-NAME. These results indicated that gNO enhanced the metastatic ability of A549 cells via, at least in part, the regulation of iNOS and MMPs.
FIG. 5.
Effects of gNO on NF-jB and c-Jun nuclear translocation levels. A549 cells were treated with 5.0lM gNO in the absence or presence L-NAME for indicated times (0-24 h), after which cells were harvested and the nuclear fraction analyzed for NF-jB (A) and c-Jun (B) expression. The nuclear protein levels were determined by Western blot. C23 was served as a nuclear internal control. The quantitative data were presented as means ± SD of three repeats from one independent study. *p < 0.05, **p < 0.01 compared with 0-h control. #p < 0.05, ##p < 0.01 compared with the respective time point of gNO-treated group. 
DISCUSSION
The role of exogenous exposure to NO in tumor biology is complex (Harmey et al., 2002) . gNO present in the gaseous phase of smoke and air pollution is a major source of exogenous NO (Leaderer, 1982; Yoshie and Ohshima, 1997) . Although the past studies ha suggested an association between gNO and lung pro-tumorgenesis, including DNA damage, proliferation, cell cycle progression and anti-apoptosis (Chen et al., 2003 (Chen et al., , 2005 Hsieh et al., 2001) , whether the exogenous NO may affect the metastatic potential of tumor cells has not been investigated. In this study, we verified the role of gNO on malignant progression of human lung carcinoma in in vitro and in vivo systems. This is the first report documenting the invasive and metastatic mechanisms of gNO.
To prioritize that gNO is a multifunction mediator of cell responses, it is important to exclude the effect of gNO on tumor cell growth. MTT data have showed that the cell viability was not significantly altered by the treatment of gNO at a concentration between 1.0 and 5.0lM (Fig. 1A) , indicating that gNO did not affect the growth of A549 cells at the doses applied in all subsequent experiments. When A549 cells were treated with gNO (5.0lM) for 24 h, the level of endogeneous NO was increased up to about 18lM (Fig. 1B) . The induction of NO release has been correlated to the cells in response to proinflammatory cytokines tumor necrosis factor-a and interleukin-1b (Roy et al., 2004) . gNO treatment was shown to enhance both the migration and invasion potential of A549 cells by wound-healing analysis and in vitro transwell assay in a dose-and time-dependent manner (Fig. 2) . Furthermore, induction of iNOS with gNO in A549 cells was correlated with the promotion of cell migration and invasion. However, the two constitutive isoforms of NOS (eNOS and nNOS) were not affected by gNO (Fig. 3A) . Expression of iNOS in the tumor neovasculature has also been reported in experimental tumors (Gauthier et al., 2004) . Moreover, several lines of direct FIG. 6 . Effects of gNO on NF-jB and AP-1 DNA binding activity. Cells were treated with 5.0lM gNO for indicated times (0-24 h) and then nuclear extracts were analyzed for NF-jB (A) and AP-1 (B) DNA binding activity using biotin-labeled NF-jB and AP-1 specific oligonucleotide by EMSA. Lane 1 represented nuclear extracts incubated with unlabeled oligonucleotide (free probe) to confirm the specificity of binding. Results from three repeated and separated experiments were similar. Note. Effect of gNO on lung colonization was determined as described in the text. The mice were euthanized 8 weeks after cell injection, and the number and tumor volume of lung metastasis, and the whole lung weight were measured. Lung nodules > 0.5 mm in diameter were counted. ND ¼ nondetected. a *p < 0.05 compared with vehicle (group 1). b# p < 0.05 compared with A549 group (group 2). evidence support a facilitator role of iNOS in tumor progression: (1) in iNOS-deficient mice, there was decreases in the development of tumor nodules in the lungs and an increase in the survival rate (Shi et al., 2000) ; (2) numerous human coloncancer cell lines were found to express NOS activity, and an engineered overexpression of iNOS in a human colonicadenocarcinoma line enhanced tumor growth and vascularity when transplanted into nude mice (Jenkins et al., 1995) . The treatment of the NOS inhibitor, L-NAME, abrogated the gNOderived iNOS expression, and also the promoted cell migration and invasion (Figs. 3B-D) . All these findings implied that the effects of gNO on A549 cells may be mediated directly and indirectly (via the induction of iNOS primarily) by the production of endogenous NO, and both sources of NO could contribute to the process of cell migration and invasion. Therefore, gNO affected the upstream of iNOS that eventually led to the malignant progression and invasiveness of lung tumor.
An increased expression of MMP-2 and MMP-9 has been shown to related to an invasive phenotype of cancer cells. In the lung, MMP-2 and MMP-9 are known to be produced by a variety of cells in vitro. MMP-2 is preferentially secreted from fibroblasts and various epithelial cells including airway epithelial cells, and MMP-9 is preferentially expressed by inflammatory cells (Gibbs et al., 1999) . Pardo et al. (1996) reported that the MMP-2 mRNA transcript is highly expressed in type II alveolar epithelial cells (e.g., A549 cells) as well as in alveolar macrophages in rat lungs exposed to hyperoxia. Furthermore, Delclaux et al. (1997) pointed out that MMP-2 in epithelial lining fluid (ELF) was a more sensitive and specific index of adult respiratory distress syndrome or at least of alveolar injury than MMP-9 in ELF in in vivo studies. These results support that MMP-2 rather than MMP-9 is a major contributor to the alteration of alveolar structure in lung injury, or even lung cancer, due to various stimulations. The present study demonstrated gNO induced the secretion of MMP-2, but not MMP-9, by A549 cells (Fig. 4A) . Although MMP-2 is a constitutive enzyme, its expression could be regulated at the transcriptional level by some stimulation, especially in NSCLC. The reasons for such diverse effects of gNO on MMP-2 and MMP-9 are not clear, however, an in vitro versus in vivo differential regulation of both MMPs expression, release and activation may account for this discrepancy. In addition, L-NAME not only had an effect on the gNO-mediated MMP-2 activity (Fig. 4A) but also altered the balance between MMP-2 and TIMP-2 (Figs. 4B-E) . According to the above observation, we presumed that the gNO-induced MMP-2/TIMP-2 imbalance was mainly iNOS-dependent.
The transcription of MMPs gene is regulated by upstream regulatory elements, including NF-jB and AP-1 binding sites (Aguirre Ghiso et al., 1999; Westermarck and Kahari, 1999) . Indeed, one or more of these binding sites have been implicated in mediating the effects of a diverse set of agents. Previous studies demonstrated that the proliferation-promoting property of gNO was mediated through the increase of AP-1 activity in MRC-5 cells, which might contribute to lung pathogenesis (Chou et al., 2002) . In addition, the protooncogenes products cFos and c-Jun, which are components of transcription factor AP-1, were overexpressed in lung cancer patients with metastasis (Volm et al., 1993) . As a result, suppression of the NF-jB, c-Fos and c-Jun activities, or blockage of the factors binding to their regulatory elements may potentially block tumor invasion (Bergman et al., 2003; Philip and Kundu, 2003) . Consistent with these findings, the treatment of gNO to A549 cells induced NF-jB and AP-1 DNA binding activity (Fig. 6 ), which was accompanied by an increase in nuclear translocation of these factors (Fig. 5) . It is therefore possible that the enhanced effect of gNO on the motility and invasion of A549 cells was via the activation of c-Jun and NF-jB and, afterward, MMP-2. Interestingly, L-NAME seemed to have only a little effect on the gNO-induced NF-jB at 6 h, whereas it almost completely blocked the activation of NF-jB at a 24 h (Fig. 5A) . Past studies had demonstrated that NO directly activated Ras at 5-10 min, leading to downstream events such as the activation of NF-jB (Lander et al., 1995) . Thus, we suggest that gNO could indirectly affect the translocation of NF-jB not only via inducing iNOS, but also via activating other factors (e.g., Ras) in an earlier treatment period. However, further investigations have to be conducted regarding the association of the gNOmediated cell migration and invasion with Ras.
There was evidence showing that the upregulation of iNOS expression involve the activation of NF-jB and the subsequent binding to the jB enhancer elements in the iNOS gene promoter (Baek et al., 2000) . Our unpublished data also demonstrated that the pretreatment of a NF-jB inhibitor, pyrrolidine dithiocarbamate could significantly repress the iNOS induction in an early gNO treatment period. This indicates the presence of a cross-talk between the early pattern of NF-jB and iNOS activation, and the subsequent MMP-2 expression and/or cell invasion. These evidences support a positive feedback regulation of NO from exogenous to endogenous.
FIG. 7.
Effects of gNO on MMPs activity in vivo. After an indicated gNO treatment in the absence or presence L-NAME, 10 6 A549 cells were injected into the lateral tail vein of SCID mice. The mice were sacrificed after 8 weeks, and zymography assay was carried out with lung tissue extracts from them. Results were representative of eight different mice. Group no. 1. vehicle (PBS); 2. A549; 3. A549 þ 2.5lM gNO; 4. A549 þ 5.0lM gNO; and 5. A549 þ 5.0lM gNO þ L-NAME.
GNO PROMOTES MALIGNANT PROGRESSION OF A549 CELLS
Based on these results, we proposed a schematic presentation of possible mechanisms for the effect of gNO on migration and invasion of A549 cells (Fig. 8) . gNO treatment induced the cell migration/invasion via iNOS activation, followed by c-Jun and/or NF-jB pathways and MMP-2 production, as well as the reduction of TIMP-2. However, the cross-talk between these two pathways is poorly understood. Most significantly, gNO administered to the metastatic A549 enhanced dramatically its metastasis to the lung in the animal model (Table 1) . Our data also showed that gNO promoted both the invasion and metastatic potential of malignant carcinoma cells in vitro and in vivo through the regulation of MMP-2 activity, which was mediated through the induction of iNOS (Fig. 7) . These results demonstrated that gNO plays a stimulatory role in malignant progression by multiple mechanisms: promotion of migration, matrix degradation and metastasis. Our findings should provide a clue for the development of novel therapeutic strategies to improve the survival of patients with advanced lung cancer. 
